Comprehensive characterization of therapeutic monoclonal antibody (mAb) structures is critical for drug development but remains challenging due to the inherent structural heterogeneity. In this study, ...

This study provides compelling evidence that SLC7A11 may serve as a potential therapeutic target for trastuzumab-resistant HER2-positive breast cancer. While the findings are well-supported by robust ...

Two more cases of Measles have been confirmed in Minnesota, bringing the total number of cases in 2025 to four, according to the Department of Health.

Two more measles cases in Minnesota, including unvaccinated child who was infectious at MOA. Brittney Ermon & Ashley Halbach KSTP. New measles cases in Minnesota. On Monday, ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Trastuzumab deruxtecan plus pertuzumab significantly extends PFS compared to THP in HER2-positive metastatic breast cancer. The combination demonstrated a 44% lower risk of disease progression or ...

CHICAGO — Results from the phase 3 DESTINY-Breast09 clinical trial found that the combination of trastuzumab deruxtecan (Enhertu®) with pertuzumab (Perjeta®) can delay cancer growth for longer than ...

The monoclonal antibody trastuzumab, targeting the extracellular domain of the HER2 protein, was the first targeted therapy approved in combination with chemotherapy in first-line metastatic ...

Results from the phase 2 segment of a phase 2/3 trial (NCT05980481) evaluating the antibody-drug conjugate disitamab vedotin (DV; Aidixi), PD-1 inhibitor toripalimab (Loqtorzi), and trastuzumab ...

1. ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic breast ...

On the basis of phase 2 studies, trastuzumab deruxtecan was approved for patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic gastric cancer or gastroesophageal ...

CHICAGO — Second-line trastuzumab deruxtecan-nxki significantly extended OS compared with paclitaxel plus ramucirumab for patients with advanced gastric cancers previously treated with ...